Sandbox:MGS: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 48: | Line 48: | ||
*Dexamethasone | *Dexamethasone | ||
*Rituximab | *Rituximab | ||
| *Peripheral Neuropathy - reversible in 61% of patients | | | ||
*Peripheral Neuropathy - reversible in 61% of patients | |||
|- | |- | ||
| DRC regimen | | DRC regimen |
Revision as of 18:13, 17 November 2015
Waldenström's macroglobulinemia Microchapters |
Differentiating Waldenström's macroglobulinemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Sandbox:MGS On the Web |
American Roentgen Ray Society Images of Sandbox:MGS |
Directions to Hospitals Treating Waldenström's macroglobulinemia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]
Treatment Regimen | Drug | Side effects |
---|---|---|
CHOP-R regimen |
|
|
Ibrutinib |
--- |
|
Rituximab |
|
|
FR regimen |
|
|
BDR regimen |
|
|
DRC regimen |
|
|
CR regimen |
|
|